Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

On Tuesday, Amgen Inc. (NASDAQ:AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines.The acquisition values Dark Blue Therapeutics at up to $840 million, including upfront and future milestones.Why Is The Acquisition Important?Dark Blue’s lead candidate, DBT 3757, is currently in IND-enabling studies for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).Leukemia is a cancer of the blood-forming tissues, like bone marrow, ...